322 related articles for article (PubMed ID: 10815887)
1. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
[TBL] [Abstract][Full Text] [Related]
2. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Gilewski TA; Ragupathi G; Dickler M; Powell S; Bhuta S; Panageas K; Koganty RR; Chin-Eng J; Hudis C; Norton L; Houghton AN; Livingston PO
Clin Cancer Res; 2007 May; 13(10):2977-85. PubMed ID: 17504999
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
[TBL] [Abstract][Full Text] [Related]
4. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
5. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
[TBL] [Abstract][Full Text] [Related]
6. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
7. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.
Gathuru JK; Koide F; Ragupathi G; Adams JL; Kerns RT; Coleman TP; Livingston PO
Vaccine; 2005 Sep; 23(39):4727-33. PubMed ID: 15978705
[TBL] [Abstract][Full Text] [Related]
8. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.
Adluri S; Gilewski T; Zhang S; Ramnath V; Ragupathi G; Livingston P
Br J Cancer; 1999 Apr; 79(11-12):1806-12. PubMed ID: 10206297
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC
Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341
[TBL] [Abstract][Full Text] [Related]
10. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
[TBL] [Abstract][Full Text] [Related]
11. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
Krug LM; Ragupathi G; Hood C; Kris MG; Miller VA; Allen JR; Keding SJ; Danishefsky SJ; Gomez J; Tyson L; Pizzo B; Baez V; Livingston PO
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6094-100. PubMed ID: 15447995
[TBL] [Abstract][Full Text] [Related]
13. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice.
Zhang S; Graeber LA; Helling F; Ragupathi G; Adluri S; Lloyd KO; Livingston PO
Cancer Res; 1996 Jul; 56(14):3315-9. PubMed ID: 8764127
[TBL] [Abstract][Full Text] [Related]
14. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1.
Musselli C; Ragupathi G; Gilewski T; Panageas KS; Spinat Y; Livingston PO
Int J Cancer; 2002 Feb; 97(5):660-7. PubMed ID: 11807794
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
Chapman PB; Morrisey D; Panageas KS; Williams L; Lewis JJ; Israel RJ; Hamilton WB; Livingston PO
Clin Cancer Res; 2000 Dec; 6(12):4658-62. PubMed ID: 11156217
[TBL] [Abstract][Full Text] [Related]
16. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides.
von Mensdorff-Pouilly S; Petrakou E; Kenemans P; van Uffelen K; Verstraeten AA; Snijdewint FG; van Kamp GJ; Schol DJ; Reis CA; Price MR; Livingston PO; Hilgers J
Int J Cancer; 2000 Jun; 86(5):702-12. PubMed ID: 10797294
[TBL] [Abstract][Full Text] [Related]
17. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
[TBL] [Abstract][Full Text] [Related]
18. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
[TBL] [Abstract][Full Text] [Related]
19. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
Musselli C; Livingston PO; Ragupathi G
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
[TBL] [Abstract][Full Text] [Related]
20. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
Slovin SF; Ragupathi G; Fernandez C; Jefferson MP; Diani M; Wilton AS; Powell S; Spassova M; Reis C; Clausen H; Danishefsky S; Livingston P; Scher HI
Vaccine; 2005 May; 23(24):3114-22. PubMed ID: 15837210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
